PDF(Pubmed)
Abstract：
iCanQuit is a smartphone application (app) proven efficacious for smoking cessation in a Phase III randomized controlled trial (RCT). This study aimed to measure whether medications approved by the US Food and Drug Administration (FDA) for smoking cessation would further enhance the efficacy of iCanQuit, relative to its parent trial comparator-the National Cancer Institute\'s (NCI\'s) QuitGuide app.
Secondary analysis of the entire parent trial sample of a two-group (iCanQuit and QuitGuide), stratified, doubled-blind RCT.
United States.
Participants who reported using an FDA-approved cessation medication on their own (n = 619) and those who reported no use of cessation medications (n = 1469).
Participants were randomized to receive iCanQuit app or NCI\'s QuitGuide app.
Use of FDA-approved medications was measured at 3 months post-randomization. Smoking cessation outcomes were measured at 3, 6 and 12 months. The primary outcome was 12-month self-reported 30-day point prevalence abstinence (PPA).
The data retention rate at the 12-month follow-up was 94.0%. Participants were aged 38.5 years, 71.0% female, 36.6% minority race/ethnicity, 40.6% high school or less education, residing in all 50 US States and smoking 19.2 cigarettes/day. The 29.6% of all participants who used medications were more likely to choose nicotine replacement therapy (NRT; 78.8%) than other cessation medications (i.e. varenicline or bupropion; 18.3 and 10.5%, respectively) and use did not differ by app treatment assignment (all P > 0.05). There was a significant (P = 0.049) interaction between medication use and app treatment assignment on PPA. Specifically, 12-month quit rates were 34% for iCanQuit versus 20% for QuitGuide [odds ratio (OR) = 2.36, 95% confidence interval (CI) = 1.59, 3.49] among participants reporting any medication use, whereas among participants reporting no medication use, quit rates were 28% for iCanQuit versus 22% for QuitGuide (OR = 1.41, 95% CI = 1.09, 1.82). Results were stronger for those using only NRT: 40% quit rates for iCanQuit versus 18% quit rates for QuitGuide (OR = 3.57, 95% CI = 2.20, 5.79).
The iCanQuit smartphone app for smoking cessation was more efficacious than the QuitGuide smartphone app, regardless of whether participants used medications to aid cessation. Smoking cessation medications, especially nicotine replacement therapy, might enhance the efficacy of the iCanQuit app.
Secondary analysis of the entire parent trial sample of a two-group (iCanQuit and QuitGuide), stratified, doubled-blind RCT.
United States.
Participants who reported using an FDA-approved cessation medication on their own (n = 619) and those who reported no use of cessation medications (n = 1469).
Participants were randomized to receive iCanQuit app or NCI\'s QuitGuide app.
Use of FDA-approved medications was measured at 3 months post-randomization. Smoking cessation outcomes were measured at 3, 6 and 12 months. The primary outcome was 12-month self-reported 30-day point prevalence abstinence (PPA).
The data retention rate at the 12-month follow-up was 94.0%. Participants were aged 38.5 years, 71.0% female, 36.6% minority race/ethnicity, 40.6% high school or less education, residing in all 50 US States and smoking 19.2 cigarettes/day. The 29.6% of all participants who used medications were more likely to choose nicotine replacement therapy (NRT; 78.8%) than other cessation medications (i.e. varenicline or bupropion; 18.3 and 10.5%, respectively) and use did not differ by app treatment assignment (all P > 0.05). There was a significant (P = 0.049) interaction between medication use and app treatment assignment on PPA. Specifically, 12-month quit rates were 34% for iCanQuit versus 20% for QuitGuide [odds ratio (OR) = 2.36, 95% confidence interval (CI) = 1.59, 3.49] among participants reporting any medication use, whereas among participants reporting no medication use, quit rates were 28% for iCanQuit versus 22% for QuitGuide (OR = 1.41, 95% CI = 1.09, 1.82). Results were stronger for those using only NRT: 40% quit rates for iCanQuit versus 18% quit rates for QuitGuide (OR = 3.57, 95% CI = 2.20, 5.79).
The iCanQuit smartphone app for smoking cessation was more efficacious than the QuitGuide smartphone app, regardless of whether participants used medications to aid cessation. Smoking cessation medications, especially nicotine replacement therapy, might enhance the efficacy of the iCanQuit app.
摘要：
目的：iCanQuit是一款智能手机应用程序（app），在一项III期随机对照试验（RCT）中被证明对戒烟有效。这项研究旨在衡量美国食品和药物管理局（FDA）批准的戒烟药物是否会进一步提高iCanQuit的疗效。相对于其父试验比较-国家癌症研究所（NCI）的QuitGuide应用程序。
方法：对两组（iCanQuit和QuitGuide）的整个父母试验样本进行二次分析，分层，双盲RCT。
方法：美国。
方法：报告自己使用FDA批准的戒烟药物的参与者（n=619）和报告未使用戒烟药物的参与者（n=1469）。
方法：参与者随机接受iCanQuit应用程序或NCI的QuitGuide应用程序。
方法：在随机化后3个月测量FDA批准的药物的使用。在3、6和12个月时测量戒烟结果。主要结果是12个月自我报告的30天点患病率禁欲（PPA）。
结果：12个月随访时数据保留率为94.0%。参与者年龄38.5岁，71.0%女性，36.6%少数民族种族/族裔，40.6%的高中或低学历，居住在美国所有50个州，每天吸烟19.2支香烟。在所有使用药物的参与者中，29.6％的人更有可能选择尼古丁替代疗法（NRT;78.8％），而不是其他戒断药物（即伐尼克林或安非他酮；18.3％和10.5％，分别）和应用治疗分配没有差异（均P>0.05）。在药物使用和应用治疗分配之间存在显著的相互作用(P=0.049)。具体来说,在报告任何药物使用的参与者中，iCanQuit的12个月戒烟率为34％，QuitGuide的12个月戒烟率为20％[优势比（OR）=2.36，95％置信区间（CI）=1.59，3.49]，而在报告没有使用药物的参与者中，iCanQuit的戒烟率为28%，QuitGuide的戒烟率为22%(OR=1.41，95%CI=1.09，1.82)。仅使用NRT的人的结果更强：iCanQuit的戒烟率为40％，QuitGuide的戒烟率为18％（OR=3.57，95％CI=2.20，5.79）。
结论：用于戒烟的iCanQuit智能手机应用程序比QuitGuide智能手机应用程序更有效，无论参与者是否使用药物来帮助戒烟。戒烟药物，尤其是尼古丁替代疗法,可能会增强iCanQuit应用程序的功效。
方法：对两组（iCanQuit和QuitGuide）的整个父母试验样本进行二次分析，分层，双盲RCT。
方法：美国。
方法：报告自己使用FDA批准的戒烟药物的参与者（n=619）和报告未使用戒烟药物的参与者（n=1469）。
方法：参与者随机接受iCanQuit应用程序或NCI的QuitGuide应用程序。
方法：在随机化后3个月测量FDA批准的药物的使用。在3、6和12个月时测量戒烟结果。主要结果是12个月自我报告的30天点患病率禁欲（PPA）。
结果：12个月随访时数据保留率为94.0%。参与者年龄38.5岁，71.0%女性，36.6%少数民族种族/族裔，40.6%的高中或低学历，居住在美国所有50个州，每天吸烟19.2支香烟。在所有使用药物的参与者中，29.6％的人更有可能选择尼古丁替代疗法（NRT;78.8％），而不是其他戒断药物（即伐尼克林或安非他酮；18.3％和10.5％，分别）和应用治疗分配没有差异（均P>0.05）。在药物使用和应用治疗分配之间存在显著的相互作用(P=0.049)。具体来说,在报告任何药物使用的参与者中，iCanQuit的12个月戒烟率为34％，QuitGuide的12个月戒烟率为20％[优势比（OR）=2.36，95％置信区间（CI）=1.59，3.49]，而在报告没有使用药物的参与者中，iCanQuit的戒烟率为28%，QuitGuide的戒烟率为22%(OR=1.41，95%CI=1.09，1.82)。仅使用NRT的人的结果更强：iCanQuit的戒烟率为40％，QuitGuide的戒烟率为18％（OR=3.57，95％CI=2.20，5.79）。
结论：用于戒烟的iCanQuit智能手机应用程序比QuitGuide智能手机应用程序更有效，无论参与者是否使用药物来帮助戒烟。戒烟药物，尤其是尼古丁替代疗法,可能会增强iCanQuit应用程序的功效。
